LINDA HAFFELFINGER: Open Payments
NPI 1619040482 · LANSDALE, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,846 in 92 payments from 19 companies in 2025. Trend: 2023 $0 · 2024 $2,525 · 2025 $1,846
Food & beverage: $1,846
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 36 | $545 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $194 |
| Ardelyx, Inc. | 6 | $138 |
| Janssen Biotech, Inc. | 4 | $130 |
| GENZYME CORPORATION | 5 | $117 |
| Ipsen Biopharmaceuticals, Inc | 4 | $101 |
| Lilly USA, LLC | 5 | $96 |
| Daiichi Sankyo Inc. | 3 | $81 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 4 | $80 |
| Aimmune Therapeutics, Inc. | 3 | $68 |
Products named: RINVOQ, IBSRELA, TREMFYA, LINZESS, DUPIXENT, ENTYVIO, IQIRVO, CREON.
Industry payments across PA — which companies pay providers there.
